Please login to the form below

Not currently logged in
Email:
Password:

Alecensa

This page shows the latest Alecensa news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Health and social care still divided, Opdivo rejected in bladder cancer, Xalkori extends reach

Daily Brief: Health and social care still divided, Opdivo rejected in bladder cancer, Xalkori extends reach

Xalkori is for now keeping one step ahead of rival treatments, such as Novartis’Zykadia, which gained NICE approval for use in ALK+ patients in January, and Roche’s Alecensa, which

Latest news

  • MSD launches EU’s first biosimilar Herceptin in UK MSD launches EU’s first biosimilar Herceptin in UK

    has insisted it can ride out the storm with new products such as multiple sclerosis therapy Ocrevus (ocrelizumab) and cancer drugs Perjeta (pertuzumab), Tecentriq (atezolizumab) and Alecensa (alectinib).

  • Pfizer files third-gen ALK inhibitor for lung cancer Pfizer files third-gen ALK inhibitor for lung cancer

    of competitive pressure from Roche’s fast-growing rival Alecensa (alectinib), a second-generation inhibitor that is well-tolerated and has the added benefit of penetrating the brain, which can help ... Alecensa saw sales double to reach around $385m in

  • Roche faces biosimilar blitz in 2018 Roche faces biosimilar blitz in 2018

    Last year, Ocrevus, Tecentriq, Perjeta and Alecensa sales drove a 5% growth for Roche, along with label extensions for existing products and approvals for new medicines Ocrevus and Hemlibra in the ... US. Schwan added: “I am particularly pleased with

  • Roche gets FDA OKs for Alecensa and Zelboraf Roche gets FDA OKs for Alecensa and Zelboraf

    Roche gets FDA OKs for Alecensa and Zelboraf. Gains US licences for first-line use in lung cancer and a rare blood cancer. ... Approval of Alecensa for front-line use in Europe is expected in the next few weeks after it was recommended by the Committee

  • Roche wins CHMP nod for Alecensa licence extensions Roche wins CHMP nod for Alecensa licence extensions

    Roche wins CHMP nod for Alecensa licence extensions. Lung cancer monotherapy set for a broader European label. ... European regulatory advisors have given their backing to new uses of Roche’s lung cancer drug Alecensa (alectinib).

More from news
Approximately 14 fully matching, plus 16 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics